W

Windlas Biotech

(NSE: WINDLAS)

WINDLAS

234.15

0.00 (0.00%)

Windlas Biotech Price Chart

Note: The data used to display charts is delayed by 15 mins as per guidelines.

Windlas Biotech Price Chart

Note: The data used to display charts is delayed by 15 mins as per guidelines.

Windlas Biotech Price Summary

Today High

236.55

Today Low

228.9

52 Week High

236.55

52 Week Low

228.9

Windlas Biotech Fundamentals

Market Cap

481.5 Cr

CASA

NA

No. Of Shares

2.2 Cr

P/E

0.0

P/B

0.0

Face Value

5.0

Dividend Yeild

NA

Book Value

310.4

Net Interest Income

19.2

Cost to Income

NA

Promoter Holdings

60.0

EPS

7.8

CAR

NA

ROE

2.4

ROCE

5.2

Profit Growth

NA

Windlas Biotech Peer Comparison

COMPANY

PRICE

MCAP (cr)

P/B

P/E

EPS

ROE

ROCE

NII

Windlas Biotech

234.15

481.5 Cr

0.0

0.0

7.8

2.4

5.2

19.2

Kaya

361

488.6 Cr

3.8

0.0

-10.8

-13.2

-1.4

44.3

Lyka Labs

124.85

443.7 Cr

16.9

0.0

-5.0

-124.7

4.4

139.5

Nectar Life Sciences

21

541.6 Cr

0.4

0.0

-3.3

-6.7

1.4

26.8

Lincoln Pharma

284.8

555.6 Cr

1.2

7.2

31.1

18.6

25.2

223.7

Artemis Medicare

61.05

569.2 Cr

1.2

41.5

5.4

2.8

5.9

183.4

FAQ’s on Windlas Biotech

About Windlas Biotech

Windlas Biotech is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, it provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to providing services and products in the CDMO market, it also sell its own branded products in the trade generics and OTC markets as well as export generic products to several countries.

The company’s CDMO Services and Products SBV is focused on providing products and services across a diverse range of pharmaceutical and nutraceutical generic products for Indian and multinational pharmaceutical companies who market such products under their own brand names to the end users. The company’s Domestic Trade Generics and OTC Brands SBV consists of (i) trade generic products; and (ii) OTC brands, which include nutraceutical and health supplement products that do not require prescription and are marketed, distributed and promoted in India under its own brand names through online and offline channels and majorly manufactured by it. Trade generic products are generic medicines, i.e. drugs for which the patents have expired, which are sold directly to the distributor and not marketed through medical representatives, and are typically used as a substitute for more expensive branded generic medicines in order to offer affordable medicines to patients by the retailers and pharmacies. The company’s Exports SBV is engaged in identifying high growth markets and opportunities in semi-regulated international markets as well as selected regulated markets, for developing and registering product applications to obtain marketing authorizations for generic medicines and health supplements and subsequently, sell such products to pharmaceutical companies and pharmacies in the respective markets.

Business area of the company

The company provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world.

Awards, accreditations and recognitions

  • 2018: The company was awarded the TV100 Industrial Excellence Award in the field of medicine.
  • 2019: The company was awarded the certificate of appreciation from the Secretary, Bureau of Energy Efficiency for valuable contributions in implementing energy efficiency and cleaner production measures under the project ‘Financing Energy Efficiency at MSMEs’.
  • 2019: The company was awarded the certificate of partnership recognizing its contribution to and participation in the Swasth Bharat Yatra, a pan-India cyclothon organised by the Food Safety and Standards Authority of India.

Major events and milestones

  • 2001: Commenced operations at Dehradun Plant - I situated at 40/1, Mohabewala Industrial Area, Dehradun 248 110 and initiated commercial production.
  • 2009: Commenced operations at Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 110.
  • 2010: Revenues crossed Rs 1,000 million for the FY 2009-10.
  • 2014: Received first USFDA inspection clearance for the WHC Plant.
  • 2014: Revenues crossed Rs 2,000 million for the FY 2013-14.
  • 2014: Commenced operations at Dehradun Plant - II situated at khasra no. 141 to 143 and 145, Mohabewala Industrial Area, Dehradun 248 110.
  • 2015: Investment of Rs 750 million from Tano India Private Equity Fund II.
  • 2017: Revenues crossed Rs 3,000 million for the FY 2016-17.
  • 2018: Launched first product in the United States from the Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun.
  • 2018: Commenced operations at Dehradun Plant - III situated at plot no. 39, Pharmacity, Selaqui, Dehradun.
  • 2021: Approval of Scheme of Amalgamation of its erstwhile subsidiary, Windlas Healthcare, with and into the company.

Trade Windlas Biotech today

Create a free portfolio in Trinkerr and earn and grow along with peers